OnADose vs H1 Mobile
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
OnADose
This educational tool assists US healthcare professionals with onabotulinumtoxinA dosing and reconstitution for conditions like chronic migraine, spasticity, and cervical dystonia. It provides important safety information and indications for approved uses.
- OnabotulinumtoxinA dosing guidance
- Reconstitution information
- Educational tool for healthcare professionals
- Information on chronic migraine
- Information on spasticity
- Information on cervical dystonia
- Important safety information
Read full descriptionHide full description
OnADose is an onabotulinumtoxinA dosing and reconstitution educational tool for spasticity, cervical dystonia, and chronic migraine. This app is intended for training use by US healthcare professionals ONLY. Patients should seek a doctor’s advice before making any medical decisions. OnabotulinumtoxinA Important Safety Information OnabotulinumtoxinA Indications Chronic Migraine -OnabotulinumtoxinA is indicated for the prophylaxis of headaches in adult patients with Chronic Migraine (≥ 15 days per month with headache lasting 4 hours a day or longer). Limitations of Use -Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month) in 7 placebo-controlled studies. Spasticity -OnabotulinumtoxinA is indicated for the treatment of spasticity in patients 2 years of age and older. Limitations of Use -OnabotulinumtoxinA has not been shown to improve upper extremity functional abilities or range of motion at a joint affected by a fixed contracture. Cervical Dystonia -OnabotulinumtoxinA is indicated for the treatment of adults with Cervical Dystonia to reduce the severity of abnormal head position and neck pain associated with Cervical Dystonia. IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of onabotulinumtoxinA and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses. Contraindications -Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation -Infection at the proposed injection site Warnings and Precautions -Spread of toxin effects; swallowing and breathing difficulties can lead to death. Seek immediate medical attention if respiratory, speech or swallowing difficulties occur -Potency Units of onabotulinumtoxinA are not interchangeable with other preparations of botulinum toxin products -Potential serious adverse reactions after onabotulinumtoxinA injections for unapproved uses -Concomitant neuromuscular disorder may exacerbate clinical effects of treatment -Use with caution in patients with compromised respiratory function -Bronchitis and upper respiratory tract infections in patients treated for spasticity Adverse Reactions The most common adverse reactions (≥5% and >placebo, if applicable) are: -Chronic Migraine: neck pain, headache -Adult Spasticity: pain in extremity -Pediatric Spasticity: upper respiratory tract infection -Cervical Dystonia: dysphagia, upper respiratory infection, neck pain, headache, increased cough, flu syndrome, back pain, rhinitis Drug Interactions -Patients receiving concomitant treatment of onabotulinumtoxinA and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of onabotulinumtoxinA may be potentiated Use in Specific Populations -Pregnancy: Based on animal data, may cause fetal harm Please see full Prescribing Information for onabotulinumtoxinA. Available at http://www.rxabbvie.com. Copyright ©2022 AbbVie. All rights reserved.
H1 Mobile
This platform connects healthcare professionals with life sciences organizations. It provides a comprehensive database of doctors, enabling targeted engagement and insights into their expertise and activities. Access is granted through organizational authorization.
- Healthcare professional database
- Doctor search and filtering
- HCP insights (research, expertise)
- Profile monitoring
- Global treatment area coverage
- Organizational access control
Read full descriptionHide full description
H1 is creating a healthier future by connecting the world with the right doctors. H1 works across the healthcare ecosystem as the trusted source for Healthcare professional information for life sciences, payers, providers, and patients. H1's Healthcare Professional Universe (HCPU) is the leading source of truth for life sciences companies to identify, segment, and engage with right doctors across all treatment areas globally. HCPU allows users to discover health care professionals (HCPs) through intuitive search and filtering and then provides insights about those HCPs including research, clinical expertise, presentations, social media activity, and more. HCPU also lets users tag HCPs to actively monitor updates to their profiles and stay up-to-date on the latest developments in a treatment area. Access to H1's services is authorized by your organization. You will have access to mobile features that have been enabled by your organization based on your role.
Screenshots
Verdict
The clearest difference is update cadence: H1 Mobile at every 3 weeks against OnADose's every 8 months. H1 Mobile also leads on ratings volume (10 vs 3). OnADose's advantage is iOS requirement (11.0 vs 13.2). On price, rating, ads and in-app purchases there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
On the App Store both sit at effectively the same score — 5.0 for OnADose against 5.0 for H1 Mobile. Both are backed by a comparable volume of ratings — 3 and 10 respectively.
OnADose ships an update every 8 months, H1 Mobile every 3 weeks. The most recent releases landed on June 11, 2026 and September 15, 2026 respectively.
| Parameter | OnADose | H1 Mobile |
|---|---|---|
| Price | Free | Free |
| Rating | 5.0 (3 ratings) | 5.0 (10 ratings) |
| Number of ratings | 3 | 10 — better |
| Update frequency | Every 8 months | Every 3 weeks — better |
| Ads | No | No |
| In-app purchases | No | No |
| Monetization | Free | Free |
| Devices | iPhone, iPod | iPhone, iPad, iPod — better |
| Requires iOS | 11.0 — better | 13.2 |
| Further details — not scored | ||
| Size | 44 MB | 55 MB |
| Age rating | 12+ | 12+ |
| Developer | AbbVie Inc | H1 Insights, Inc. |
Customer experience
OnADose
H1 Mobile
In-app purchases
OnADose
No in-app purchases
H1 Mobile
No in-app purchases









